Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• New drugs bring dual benefits for ‘intertwined’ diabetic kidney disease, CVD Regina Schaffer
• Addition of P2Y12 inhibitor fails to benefit noncritically ill patients with COVID-19 Brian Ellis
• Closure systems for TAVR procedures vary by complications, time to hemostasis Erik Swain
• Empagliflozin beneficial in ‘true’ HFpEF with higher ejection fraction Regina Schaffer
• HFpEF treatment, CV effects of COVID-19 among top issues of 2021 Erik Swain
• Mesenchymal precursor cell therapy fails to lower HF events, but may confer other benefits Erik Swain
• Milvexian prevents VTE without raising bleeding after knee arthroplasty Erik Swain; Ryan Lawrence
• New guideline advises not limiting coronary revascularization based on race, sex Erik Swain
• Sex differences in HF: Risk factors, presentation, knowledge gaps vary between women, men Scott Buzby
• SURTAVI: TAVR remains noninferior to surgery in intermediate-risk patients at 5 years Erik Swain
• Symptoms of vaccine-related myocarditis in young people mild, resolve quickly Scott Buzby
• Telecardiology advances rapidly in COVID-19 era L. Samuel Wann, MD, MACC, FESC
• Ultrasound renal denervation may be beneficial in hypertension at 6 months Erik Swain
• HIV infection associated with 68% increased risk for HF Erin T. Welsh, MA
• ACTIV-4A
• AXIOMATIC-TKR
• CHIEF-HF
• CHOICE-CLOSURE
• DREAM-HF
• GIRAF
• J-HOP
• OPT-PEACE